The Journal of infectious diseases · 2026
HIV-1 APOBEC-context Mutations Detected by Next-Generation Sequencing in Plasma: Implications for Drug Resistance Interpretation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Illescas-López Marta, Muñoz Báez Paloma, de Salazar Adolfo, Delgado Rafael, Iborra Asunción, Galán Juan Carlos, Carracedo Raquel, Sigcha Mayra, López-Causape Carla, Fuentes Ana, Aguilera Antonio, Marco-Sánchez Cristina, García Federico, CoRIS
Аннотация
BACKGROUND: APOBEC3-mediated cytidine deamination produces G→A substitutions in HIV genomes, described in proviral DNA but detectable in plasma HIV-1 RNA using NGS. APOBEC-signature mutations reflect G→A enrichment substitutions, whereas APOBEC-context mutations are substitutions at drug resistance-associated positions compatible with APOBEC editing. We evaluated theirprevalence and impact on resistance interpretation.
METHODS: We retrospectively analysed plasma HIV-1 NGS-sequences from antiretroviral-naive individuals in 2022-2023. Sequencing was performed in participating laboratories, and FASTQ centrally reanalyzed using DeepChek. APOBEC-signature mutations, APOBEC-context drug resistance mutations (DRMs), and stop codons were assessed in protease, reverse transcriptase, and integrase at 1%, 3%, and 5% thesholds.
RESULTS: Among 290 individuals, 268 had complete NGS. At 1%, APOBEC-signature mutations were detected in 159 individuals and APOBEC-context DRMs in 64 (22%). Both patterns coexisted in 52 (18%), decreasing to 17 (6%) and 8 (3%) at 3% and 5% thresholds. Certain mutations, including M184I, G190E, G140S, and R263K, remained detectable at higher thresholds. R263K co-occurred with multiple APOBEC-signature mutations and stop codons indicating extensive APOBEC-mediated editing.
CONCLUSIONS: APOBEC-associated mutations are detectable in plasma HIV-1 RNA and may affect resistance interpretation. Conservative frequency thresholds (5%) APOBEC-signatures evaluation may reduce misclassification of APOBEC-induced variants as clinically relevant resistance.
METHODS: We retrospectively analysed plasma HIV-1 NGS-sequences from antiretroviral-naive individuals in 2022-2023. Sequencing was performed in participating laboratories, and FASTQ centrally reanalyzed using DeepChek. APOBEC-signature mutations, APOBEC-context drug resistance mutations (DRMs), and stop codons were assessed in protease, reverse transcriptase, and integrase at 1%, 3%, and 5% thesholds.
RESULTS: Among 290 individuals, 268 had complete NGS. At 1%, APOBEC-signature mutations were detected in 159 individuals and APOBEC-context DRMs in 64 (22%). Both patterns coexisted in 52 (18%), decreasing to 17 (6%) and 8 (3%) at 3% and 5% thresholds. Certain mutations, including M184I, G190E, G140S, and R263K, remained detectable at higher thresholds. R263K co-occurred with multiple APOBEC-signature mutations and stop codons indicating extensive APOBEC-mediated editing.
CONCLUSIONS: APOBEC-associated mutations are detectable in plasma HIV-1 RNA and may affect resistance interpretation. Conservative frequency thresholds (5%) APOBEC-signatures evaluation may reduce misclassification of APOBEC-induced variants as clinically relevant resistance.